Alpha-gal syndrome (AGS) — the tick-borne allergy to mammalian meat and other animal products, is no longer a regional curiosity. Experts report that cases are moving beyond the Mid-Atlantic and South into the Great Lakes and central U.S., with growing recognition worldwide. The message from front-line researchers and the CDC is clear — even if AGS hasn't been discovered in your neighborhood yet, the odds that it soon may be are rising (McKnight, 2025, October 01).1 Severity of symptoms can vary among patients. Galactose-α-1,3-galactose (alpha-gal), is a carbohydrate present in most mammals (although not in primates). In the U.S., tick saliva, most often from the lone star tick (Amblyomma americanum), carries proteins that deliver alpha-gal and trigger IgE-mediated sensitization. Not all bites trigger the development of AGS, and the severity varies. Susceptibility factors remain unclear. AGS is unusual among food allergies for at least 2 reasons.
Symptoms include:
The CDC now warns AGS can be fatal, and has issued its first clinical guidance. Epinephrine should be readily available and used promptly for systemic reactions. AGS is increasing rapidly. From the first 24-case description in 2009 to an estimated 450,000 reported cases in the U.S. by mid 2023, recognition of this problem has grown dramatically. Awareness may explain part of the increase, but experts also point to more tick bites, primarily due to expanding deer populations (the main host for lone star ticks), land-use changes that increases human–deer/tick contact, and climate-driven deer tick range expansion. Although the lone star tick dominates exposure risk in the U.S., other ticks have been implicated globally (for example, Ixodes ricinus in Europe). Early U.S. data suggest additional species, including the deer tick (Ixodes scapularis) and the Asian longhorned tick (Haemaphysalis longicornis)may also carry alpha-gal or convey similar risk. Allergy symptoms sometimes fade in the long-term. In many cases, sensitization fades over 3–5 years, but each new tick bite can “reset the clock.” Ongoing tick exposure therefore prolongs disease and complicates individual cases. AGS is not covered by the allergy related labeling laws. Avoiding allergenic foods is harder than it sounds, because alpha-gal–containing ingredients are not labeled to identify risky ingredients. Gelatin may be listed simply as “gelatin” without identifying the animal source. Policy proposals to require alpha-gal labeling have been considered, but none have passed. So for now, at least, hidden exposures remain common. In some cases, AGS can pose a special risk for MC patients. Note how closely some of the symptoms of AGS resemble the symptoms of MC, so that AGS reactions might be mistaken for an MC flare, in some cases. Specifically: diarrhea hives (for those of us who have histamine issues associated with MC) Be especially mindful of respiratory symptoms (if they are present), since those are usually not associated with MC, and in some cases they can lead to a fatal outcome. If you suspect that you might have AGS:
And for those of us who don't have AGS: It definitely behooves us to take personal protective measures when in tick habitat, especially around bushes, trees, and tall grass. And remember, ticks can jump. Inspect for and remove any ticks promptly. Taking measures to avoid becoming infected with AGS may seem to be bothersome, but minimizing the risk is much less bothersome than avoiding mammalian meat after an allergy develops. The Bottom line: AGS has moved from a rare curiosity to a mainstream clinical reality. It's tick-initiated, IgE-mediated, delayed in onset, and potentially fatal, but often remits without new bites. As cases spread north and west in the U.S. and continue to surface globally, when outdoors, everyone should remain vigilant, and do their best to avoid tick bites. If infected, patients should recognize that safety gaps in labeling exist, and be especially careful when buying processed foods. Reference 1. McKnight, W. (2025, October 01). Alpha-Gal Syndrome, the Meat Allergy, Expands Its Reach. Medscape, Retrieved from https://www.medscape.com/viewarticle/alpha-gal-syndrome-meat-allergy-expands-its-reach-2025a1000qcz
0 Comments
Official medical guidelines often contain worrisome problems. One of those, for example, is the disparity between minimal vitamin D threshold levels set by official guidelines, and the levels that epidemiological data suggest are optimal for much broader disease prevention. This disconnect is real and has been the subject of growing debate among researchers, clinicians, and patient advocates. Does this risky gap exists because of unintended oversight, or a more systemic incentive problem. Official medical vitamin D guidelines reflect minimal standards. At the core of the problem is the fact that the medical guidelines list minimal thresholds that are designed to prevent acute deficiency disease — not to optimize health. For example, medical guidelines from the Institute of Medicine or Endocrine Society define deficiency in terms of preventing:
These guidelines typically set the sufficiency cutoff around 20–30 ng/mL (50–75 nmol/L). But these levels are based on outdated endpoints and ignore the non-skeletal roles of vitamin D, such as:
By contrast, epidemiological studies routinely associate 40–60 ng/mL (100–150 nmol/L) with lower risks of:
Fear of toxicity has led to overly conservative guidelines. Regulators remain cautious because:
However, numerous studies show that levels up to 100 ng/mL are safe and that daily supplementation of 2000–5000 IU is rarely associated with harm, especially when magnesium and vitamin K2 intake are adequate. Yet, the official upper intake limit remains at 4000 IU/day, a conservative figure not supported by more recent safety data. Guideline selecting committees reflect medical conservatism and risk aversion. Organizations such as the Endocrine Society tend to prioritize:
This conservative approach leads to an unrealistic "wait for perfect proof" mentality, despite real-world, population-level correlations suggesting otherwise. Pharmaceutical and insurance incentives tend to disincentive prevention. While it may be unfair to claim the system is intentionally keeping people deficient to drive healthcare profits, structural incentives do create passive disincentives for prevention:
In this sense, the system, as designed, doesn’t reward optimal public health outcomes—it rewards sick care. Guidelines recommend inadequate testing and diagnostic practices. Routine vitamin D testing is discouraged for the general population under current guidelines, despite:
Note that this is similar to the neglect seen with magnesium testing, where reliance on inaccurate serum levels prevents effective diagnosis and intervention. The message sent to the public is confusing and contradictory. Medical authorities often:
This has led to public confusion, under-supplementation, and persistent population-level deficiency—despite decades of emerging research. So do the guidelines encourage sickness rather than disease prevention? There's no clear evidence of any coordinated conspiracy, of course, but:
all contribute to the persistence of low thresholds that serve institutional interests more than patient well-being. In that light, it's fair to argue the system is not designed to promote optimal health. It manages disease reactively rather than preventing it proactively. Vitamin D levels are especially important for IBD patients. Research shows that vitamin D deficiency affects up to 100% of Crohn's disease patients and 45% of those with ulcerative colitis (Johnson, 2025, May 20).1 The deficiency is not merely a result of disease activity — it likely contributes to its onset. Mechanistically, low vitamin D leads to:
Low vitamin D correlates with increased disease activity, more frequent surgeries, higher relapse rates, and poor treatment responses. A 2023 Cochrane review even found reduced relapse rates in patients supplementing with vitamin D, although evidence quality limited definitive conclusions. Another study followed 5,474 IBD patients for 13 years and found that those with adequate vitamin D levels had significantly reduced bowel resection risks — by 34% in IBD overall and 46% in ulcerative colitis (Dan et al., 2024).2 The takeaway: Despite self-serving and often confusing official vitamin D guidelines:
Additional evidence of the safety of higher doses: The Calgary vitamin D study: was a three year, double-blind, random controlled study (RCT) involving adults aged 55–70, and compared daily doses of either 4000 IU or 10,000 IU of vitamin D (Burt et al., 2019).3 The findings showed that both 4000 and 10,000 IU per day were well-tolerated. Bone density was generally unaffected, but was slightly decreased at the highest does, suggest the safety, but no skeletal benefit at high levels in already sufficient adults. The VIDAMS study (multiple sclerosis): compared 5000 IU per day versus 600 IU per day in relapsing remitting multiple sclerosis patients (Cassard et al., 2023).4 The findings showed that the higher dose yielded fewer active MRI lesions, indicating potential benefit beyond bone health. systematic review and meta-analysis: based on 32 reviews of clinical trials involving 8400 children who received high-dose vitamin D treatments ranging from 1200 to 10,000 IU per day, and bolus doses ranging from 30,000 IU per week to a single dose of 600,000 IU, found that no increased risk of serious adverse events was associated with high-dose vitamin D treatments (Brustad et al., 2022).5 Clearly: The healthcare system is focused on treating health problems, rather than preventing health problems. In all fairness though, I note that virtually no one goes to their doctor to learn how to prevent health problems — they go to their doctor to seek treatment for health problems. References 1. Johnson, D. A. (2025, May 20). The Overlooked Link Between Vitamin D and GI Health. Medscape, Retrieved from https://www.medscape.com/viewarticle/overlooked-link-between-vitamin-d-and-gi-health-2025a1000bki 2. Dan, L., Wang, S., Chen, X., Sun, Y. Fu, T., Deng, M., . . . Wang, X. (2024). Circulating 25-hydroxyvitamin D concentration can predict bowel resection risk among individuals with inflammatory bowel disease in a longitudinal cohort with 13 years of follow-up. International Journal of Surgery, [Published online]. Retrieved from https://journals.lww.com/international-journal-of-surgery/abstract/9900/circulating_25_hydroxyvitamin_d_concentration_can.1249.aspx 3. Burt, L. A., Billington, E. O., Rose, M. S., Raymond, D. A., Hanley, D. A., and Boyd, S. K. (2019). Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. JAMA, 322(8), pp 736–745, Retrieved from https://pubmed.ncbi.nlm.nih.gov/31454046/ 4. Cassard, S. D., Fitzgerald, K. C., Qian, P., Emrich, S. A., Azevedo, C. J., Goodman, A.D., . . . Mowry, E. M. (2023) High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial. EClinicalMedicine, 13;59,101957. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37125397/ 5. Brustad, N., Yousef, S., Stokholm, J., Bønnelykke, K., Bisgaard, H., and Chawes, B. L. (2022). Safety of High-Dose Vitamin D Supplementation Among Children Aged 0 to 6 Years: A Systematic Review and Meta-analysis. JAMA Network Open, 5(4). e227410 Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791031
A study from the University of Bonn, claimed to be groundbreaking, has identified a powerful new compound that may offer relief for patients suffering from hard-to-treat allergic and inflammatory conditions, including irritable bowel syndrome (IBS), asthma, chronic pruritus, and potentially microscopic colitis (MC) and other IBDs. The compound, named PSB-172656, works by blocking a little-known immune receptor called MRGPRX2, which is found on mast cells. Mast cells are heavily involved in inflammatory reactions, especially those that occur without IgE antibodies,such as drug-induced allergies, neuroinflammation, or non-IgE mediated hypersensitivity. The research was published in Signal Transduction and Targeted Therapy and widely reported by Medical Xpress on April 24, 2025 (Al Hamwi, et al., 2025; Seiler, 2025, April 24).1, 2 Note that the receptor MRGPRX2 is primarily involved in non-IgE mediated mast cell activation. It does not directly bind IgA, and IgA immune complexes are not known to activate mast cells through MRGPRX2. Instead, MRGPRX2 is activated by other signals such as:
In other words, MRGPRX2 is part of a non-antibody, direct activation system, distinct from classic antibody-driven responses. How does this compare with normal IgE and IgA reaction pathways? IgE Pathway: IgE antibodies bind to FcεRI receptors on mast cells. When allergens cross-link these IgE molecules, mast cells rapidly release histamine and other inflammatory mediators, causing classic allergic reactions like hives or anaphylaxis. MRGPRX2 Pathway: Certain peptides, medications, and irritants directly activate MRGPRX2 receptors on mast cells without needing antibodies. This causes rapid mast cell degranulation and inflammation, often seen in drug reactions and chronic inflammation. IgA Pathway: IgA antibodies mainly interact with FcαRI (CD89) receptors on immune cells (such as macrophages and neutrophils, rarely mast cells directly). In special cases, IgA immune complexes can trigger inflammation indirectly, but mast cell activation through IgA is much less common and not through MRGPRX2. Therefore, mast cells can be activated through IgE for classic allergies, through MRGPRX2 for direct non-antibody triggers, and only rarely and indirectly through IgA immune complexes—each pathway driving inflammation in different ways. Here's why MRGPRX2 matters. MRGPRX2 is a mast cell receptor involved in non-traditional allergic responses and chronic inflammatory signaling. Unlike classic IgE-mediated allergic reactions (like hay fever or food allergies), MRGPRX2 triggers localized or systemic inflammation in response to certain medications, neuropeptides, and environmental stimuli. This receptor is implicated in a variety of painful and difficult-to-treat conditions, including:
The University of Bonn researchers found that PSB-172656 is capable of binding to and inhibiting MRGPRX2 with extremely small (subnanomolar) potency, preventing mast cell degranulation and the release of inflammatory mediators. The compound stopped anaphylactic reactions in mice and reduced local inflammation in tracheal and skin models. It was shown to be highly selective for MRGPRX2 and its mouse counterpart MRGPRB2. The effect was replicated in human skin mast cells and mast cell lines, confirming its potential relevance in human disease. The molecule was engineered for metabolic stability, low toxicity, and prolonged action, making it a strong candidate for drug development. Why might this matter for MC patients? Although the study did not specifically test PSB-172656 regarding MC, the mechanism of action and targeted pathway suggest strong potential relevance:
Will this discovery resolve MC cases that are refractive to treatment? For MC patients, many of whom struggle with ongoing symptoms despite dietary changes and medical treatments using corticosteroids, this novel MRGPRX2 blocker might one day offer a targeted, non-steroidal alternative. As understanding of mast cell-related gut inflammation grows, therapies like PSB-172656 may finally bring relief to those whose condition defies conventional treatment. References 1. Al Hamwi, G., Alnouri, M.W., Verdonck, S., Leonczak, P., Chaki, S., Frischbutter, S., . . . Müller, C. E. (2025). Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models. Signal Transduction Targeted Therapy, (10)128. Retrieved from https://www.nature.com/articles/s41392-025-02209-8 2. Seiler, J. (2025, April 24), Bioactive compound blocks key immune receptor to ease hard-to-treat allergic reactions. Medical Xpress, Retrieved from https://medicalxpress.com/news/2025-04-bioactive-compound-blocks-key-immune.html
|
AuthorWayne Persky Archives
March 2026
Categories |
Offices: 19242 Darrs Creek Rd, Bartlett, Texas 76511-4460
RSS Feed 
